Meet Salma Tamam: The Egyptian Biotech Founder Making Waves in Africa's Business Heroes Competition

From developing molecular diagnostic solutions to competing for one of Africa's most prominent entrepreneurship awards, Dr. Salma Tamam, founder and CEO of the Egyptian company Reme-D, is entering a new phase in her journey. She's been selected among the top 20 entrepreneurs in the sixth edition of Africa’s Business Heroes (ABH) 2026 competition, qualifying for the semi-finals. This qualification places Tamam among a group of African entrepreneurs vying to reach the competition's grand finale and compete for a share of the total $1.5 million in prize money. The ABH 2026 semi-finalist list includes twenty entrepreneurs from 12 African countries, working in diverse sectors such as FinTech, AgriTech, manufacturing, ClimateTech, education, healthcare, and biotechnology. Salma Tamam's qualification represents an Egyptian presence in the health tech and biotechnology sector through Reme-D, a company dedicated to developing diagnostic solutions aimed at making disease detection easier and more accessible for resource-limited environments.

Who is Salma Tamam?

Salma Tamam is the founder and CEO of Reme-D. She has a strong scientific background in biotechnology, holding a PhD in nanomedicine from the University of Bonn in Germany, alongside extensive experience in biotechnology and the development of diagnostic solutions. Reme-D was launched with the goal of developing innovative, locally-made diagnostic solutions and laboratory devices in Egypt and across the Middle East and Africa. The company specifically focuses on the needs of markets facing challenges in healthcare infrastructure and access to advanced medical technologies. Tamam's vision stems from a problem that goes beyond developing a new medical test: how to provide accurate and reliable diagnoses in areas that don't necessarily have the advanced laboratory capabilities found in major medical centers.

Early Experience with COVID-19 Diagnosis

Salma Tamam's name rose to prominence in the field of biotechnology and diagnostics during the COVID-19 pandemic. She led the team that developed a local COVID-19 diagnostic test in Egypt in 2020. This achievement marks a significant milestone in her scientific and entrepreneurial journey, combining research and development with a response to an urgent health need during a period of immense pressure on healthcare systems and global diagnostic supply chains. Tamam also received the She's Next award, launched by Visa in collaboration with Commercial International Bank (CIB), in recognition of her entrepreneurial journey and innovation.

What Does Reme-D Offer?

Reme-D focuses on molecular diagnostics, a field that relies on analyzing nucleic acids to detect pathogens. The company's portfolio includes solutions for nucleic acid extraction, along with molecular tests for detecting a number of pathogens, including HIV, cytomegalovirus, human papillomavirus, hepatitis B and C viruses, and Mycobacterium tuberculosis, which causes tuberculosis. The company also develops a range of products related to molecular diagnostics, including RemeMix, RemeMix Plus, RemeMix Green, and RemeMix Green Plus. But Reme-D's work isn't limited to human diagnostics; its solutions also include applications related to animal diseases, as well as products specifically for research use.

Resource-Limited Regions

Reme-D targets one of the main problems facing healthcare systems in resource-limited regions: the difficulty of accessing advanced diagnostic tests. Some diagnostic technologies require equipped laboratories, specific temperatures and storage conditions, and supply chains and infrastructure that may not be readily available in remote or low-resource areas. That's why the company is working to develop solutions that consider these conditions, focusing on simplifying testing procedures, ensuring stability in hot and humid climates, and reducing costs. This approach aims to expand the use of molecular diagnostic technologies, so they don't remain exclusive to high-capacity medical facilities.

Health Technology and the Diagnostic Gap

Through Reme-D, Salma Tamam doesn't just focus on the scientific aspect of diagnostics, but also on the usability of technology in the environments that need it most. The company strives to develop tests that are easier to operate, while considering the climatic and logistical conditions of the target markets. This is part of Reme-D's broader philosophy: developing advanced diagnostic technology isn't enough if its cost or operational requirements prevent its use in the most needy areas. Therefore, the company combines biotechnology and molecular diagnostics to develop solutions aimed at reaching a larger number of patients and healthcare providers.

From Egypt to Global Markets

Reme-D is based in Egypt, with a declared presence in Cairo, New York, and Athens. This expansion reflects the company's direction towards developing biotechnology activities that extend beyond the Egyptian market, targeting markets that face challenges in accessing advanced diagnostic solutions. The company aims to leverage research and development to provide products that can be used in various medical and research environments.

Research and Innovation

Reme-D places scientific research and innovation at the core of its model, striving to transform developments in biotechnology into usable diagnostic products. The company doesn't just develop commercial products; it also provides solutions that can be used in research applications, opening the door for collaboration with researchers and institutions working in life sciences. In doing so, the company moves between scientific research and commercial development, in an effort to build solutions that combine diagnostic performance with usability in target markets.

Qualifying for the ABH 2026 Semi-Finals

Salma Tamam's qualification for the Africa’s Business Heroes 2026 semi-finals marks a new milestone in Reme-D's journey, after the company was selected among the African projects that reached the top 20 qualifiers. Tamam will compete in the next stage alongside entrepreneurs from 12 African countries, with only 10 advancing to the grand finale. Those who qualify for the final stage will have the opportunity to compete for a share of the competition's total prize money of $1.5 million. Egypt is participating in the ABH 2026 semi-finals with four projects representing different sectors, including Reme-D led by Salma Tamam in health tech and biotechnology, alongside Simplex CNC, FreshSource, and Tagaddod. This diversity places Egyptian companies within a broader map of African entrepreneurship, where companies from industrial, agricultural, financial, health, and climate sectors compete to attract attention, funding, and regional expansion.

What Makes Salma Tamam's Experience Unique?

Salma Tamam's experience combines an academic background in nanomedicine, expertise in biotechnology, and entrepreneurship in developing diagnostic solutions. The importance of Reme-D's experience lies in its attempt to transform scientific knowledge and molecular technologies into practical solutions that can be used in environments that don't always have advanced medical infrastructure. With her advancement to the ABH 2026 semi-finals, Tamam moves to a new stage of competition, where the challenge is twofold: proving the scientific and commercial value of the solutions Reme-D develops, and demonstrating its ability to address a health problem that extends beyond the borders of the Egyptian market. As Tamam prepares to compete for a spot in the final, Reme-D continues to develop its molecular diagnostic solutions, with a clear goal in mind: to make accurate medical diagnosis more accessible, especially for regions suffering from a lack of healthcare resources.